Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis

Trial Profile

Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ACCEPT
  • Sponsors Centocor
  • Most Recent Events

    • 09 Feb 2019 1-year safety data from 12 ustekinumab registrational trials published in the Drug Safety.
    • 16 Jun 2018 Results evaluating Cellular and Molecular Changes in response to selective Il-23 Blockade vs Dual Il-12/23 blockade in Psoriasis Skin presented at the 19th Annual Congress of the European League Against Rheumatism
    • 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top